You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 23, 2024

~ Buy the VTAMA (tapinarof) Drug Profile, 2024 PDF Report in the Report Store ~

VTAMA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Vtama, and what generic alternatives are available?

Vtama is a drug marketed by Dermavant Sci and is included in one NDA. There are nine patents protecting this drug.

This drug has sixty-nine patent family members in thirty-six countries.

The generic ingredient in VTAMA is tapinarof. One supplier is listed for this compound. Additional details are available on the tapinarof profile page.

DrugPatentWatch® Generic Entry Outlook for Vtama

Vtama will be eligible for patent challenges on May 23, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Summary for VTAMA
International Patents:69
US Patents:9
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 60
Patent Applications: 100
Drug Prices: Drug price information for VTAMA
What excipients (inactive ingredients) are in VTAMA?VTAMA excipients list
DailyMed Link:VTAMA at DailyMed
Drug patent expirations by year for VTAMA
Drug Prices for VTAMA

See drug prices for VTAMA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VTAMA
Generic Entry Date for VTAMA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CREAM;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VTAMA

US Patents and Regulatory Information for VTAMA

VTAMA is protected by nine US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VTAMA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VTAMA

Topical pharmaceutical compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Topical pharmaceutical compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS

Process for preparing tapinarof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting VTAMA

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dermavant Sci VTAMA tapinarof CREAM;TOPICAL 215272-001 May 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dermavant Sci VTAMA tapinarof CREAM;TOPICAL 215272-001 May 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Dermavant Sci VTAMA tapinarof CREAM;TOPICAL 215272-001 May 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Dermavant Sci VTAMA tapinarof CREAM;TOPICAL 215272-001 May 23, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VTAMA

When does loss-of-exclusivity occur for VTAMA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 18365241
Estimated Expiration: ⤷  Sign Up

Patent: 23274224
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2020009158
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 82115
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 20001226
Estimated Expiration: ⤷  Sign Up

Patent: 23000154
Estimated Expiration: ⤷  Sign Up

China

Patent: 1511357
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 20007018
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 06725
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 4439
Estimated Expiration: ⤷  Sign Up

Patent: 4090
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 12664
Estimated Expiration: ⤷  Sign Up

Patent: 66399
Estimated Expiration: ⤷  Sign Up

Patent: 21063100
Estimated Expiration: ⤷  Sign Up

Patent: 21169482
Estimated Expiration: ⤷  Sign Up

Patent: 21502333
Estimated Expiration: ⤷  Sign Up

Patent: 23002516
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 20004785
Estimated Expiration: ⤷  Sign Up

Patent: 22015106
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 20116424
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 202002576T
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 200087786
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VTAMA around the world.

Country Patent Number Title Estimated Expiration
Australia 2023274224 PROCESS FOR PREPARING TAPINAROF ⤷  Sign Up
Israel 282304 תכשירים רוקחיים לשימוש מקומי (Topical pharmaceutical compositions) ⤷  Sign Up
Eurasian Patent Organization 201792559 ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ МЕСТНОГО ПРИМЕНЕНИЯ ⤷  Sign Up
Denmark 3297605 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.